Histamine phosphate, Ceplene(histamine dihydrochloride)
Ceplene (histamine dihydrochloride) is a small molecule pharmaceutical. Histamine dihydrochloride was first approved as Histamine phosphate on 1982-01-01. It is used to treat allergic rhinitis seasonal and urticaria in the USA. It has been approved in Europe to treat myeloid leukemia acute.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Histamine phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HISTAMINE PHOSPHATE | Eli Lilly | N-000734 DISCN | 1982-01-01 | 3 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic rhinitis seasonal | EFO_0003956 | D006255 | J30 |
| urticaria | EFO_0005531 | D014581 | L50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
45 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | 1 | — | — | 2 | 4 |
| Allergic rhinitis | D065631 | J30.9 | 2 | 1 | — | — | 2 | 4 | |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 2 | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | D46 | 1 | 1 | — | — | — | 1 | |
| Myelomonocytic leukemia chronic | D015477 | C93.1 | 1 | 1 | — | — | — | 1 | |
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | 1 | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | 3 | 4 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pruritus | D011537 | HP_0000989 | L29 | — | — | — | — | 12 | 12 |
| Peptic ulcer | D010437 | HP_0004398 | K27 | — | — | — | — | 2 | 2 |
| Neuralgia | D009437 | EFO_0009430 | — | — | — | — | 1 | 1 | |
| Skin diseases | D012871 | L00-L99 | — | — | — | — | 1 | 1 | |
| Acute pain | D059787 | R52 | — | — | — | — | 1 | 1 | |
| Food hypersensitivity | D005512 | EFO_1001890 | — | — | — | — | 1 | 1 | |
| Diet therapy | D004035 | — | — | — | — | 1 | 1 | ||
| Chronic urticaria | D000080223 | L50.8 | — | — | — | — | 1 | 1 | |
| Bronchial diseases | D001982 | — | — | — | — | 1 | 1 | ||
| Cough | D003371 | HP_0012735 | R05 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | HISTAMINE DIHYDROCHLORIDE |
| INN | — |
| Description | Histamine dihydrochloride (INN, trade name Ceplene) is a salt of histamine that is used as a drug for the prevention of relapse in patients diagnosed with acute myeloid leukemia (AML).
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cl.Cl.NCCc1c[nH]cn1 |
Identifiers
| PDB | — |
| CAS-ID | 56-92-8 |
| RxCUI | 142136 |
| ChEMBL ID | CHEMBL1533310 |
| ChEBI ID | — |
| PubChem CID | 5818 |
| DrugBank | DBSALT002193 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,491 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,927 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more